M&T Bank Corp Has $1.37 Million Stock Position in IQVIA Holdings Inc. $IQV

Key Points

• M&T Bank Corp cut its position in IQVIA by 78.7% in Q4, selling 22,514 shares and leaving a holding of 6,096 shares worth $1.374 million.
• IQVIA beat quarterly expectations (EPS $3.42 vs. $3.40; revenue $4.36B vs. $4.24B), provided FY2026 EPS guidance of 12.55–12.85, and carries a consensus analyst target of $226.63 with a majority "Buy" rating.
• Institutional investors own about 89.62% of IQVIA, with several funds building or increasing large stakes (e.g., Candriam now holds 272,747 shares worth ~$51.8M), indicating strong institutional interest.

M&T Bank Corp lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 78.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,096 shares of the medical research company's stock after selling 22,514 shares during the quarter. M&T Bank Corp's holdings in IQVIA were worth $1,374,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Eubel Brady & Suttman Asset Management Inc. acquired a new position in IQVIA during the 3rd quarter worth approximately $14,278,000. Eagle Rock Investment Company LLC boosted its position in IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company's stock worth $8,800,000 after acquiring an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd acquired a new position in IQVIA during the 3rd quarter worth approximately $4,008,000. EDENTREE ASSET MANAGEMENT Ltd acquired a new position in IQVIA during the 3rd quarter worth approximately $7,368,000. Finally, Candriam S.C.A. boosted its position in IQVIA by 61.2% during the 3rd quarter. Candriam S.C.A. now owns 272,747 shares of the medical research company's stock worth $51,806,000 after acquiring an additional 103,567 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Down 1.6%

IQV opened at $156.42 on Thursday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The stock's fifty day simple moving average is $169.57 and its 200 day simple moving average is $201.87. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market cap of $26.55 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 1.63 and a beta of 1.39.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion for the quarter, compared to analysts' expectations of $4.24 billion. During the same quarter in the prior year, the business earned $3.12 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

Analysts Set New Price Targets

IQV has been the topic of a number of analyst reports. TD Cowen upgraded IQVIA from a "hold" rating to a "buy" rating and upped their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $220.00 and set a "buy" rating on the stock in a research note on Friday, February 6th. Wall Street Zen upgraded IQVIA from a "hold" rating to a "buy" rating in a research note on Sunday, April 19th. JPMorgan Chase & Co. dropped their price objective on IQVIA from $255.00 to $225.00 and set an "overweight" rating on the stock in a research note on Friday, February 6th. Finally, Evercore reiterated an "outperform" rating and set a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $226.63.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.